calcitonin gene-related peptide receptor antagonist

This page covers all calcitonin gene-related peptide receptor antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting calcitonin gene-related peptide receptor, Calcitonin gene-related peptide type 1 receptor, Calcitonin gene-related peptide 1.

Targets

calcitonin gene-related peptide receptor · Calcitonin gene-related peptide type 1 receptor · Calcitonin gene-related peptide 1 · calcitonin gene-related peptide receptor (CGRPR) · calcitonin receptors · Calcitonin gene-related peptide 1, Calcitonin gene-related peptide 2 · calcitonin receptor · Amylin receptor AMY2, Calcitonin receptor, Amylin receptor AMY1 · Calcitonin receptor · Calcitonin gene-related peptide receptor

Marketed (18)

• Rimegepant 75mg every other day dosing · Pfizer · Neuroscience · 798
  Rimegepant targets the calcitonin gene-related peptide receptor to treat migraines.
• Ubrelvy · AbbVie · Neuroscience · 664
  Ubrelvy blocks the action of a molecule called calcitonin gene-related peptide, which is involved in migraine pain.
• Vyepti · Lundbeck Seattle BioPharmaceuticals, Inc. · Neuroscience · 300
  Vyepti works by blocking the action of calcitonin gene-related peptide 1, a molecule involved in migraine pain.
• Qulipta · AbbVie · Neuroscience · 201
  Qulipta works by blocking the action of a natural chemical called calcitonin gene-related peptide type 1, which is involved in migraine pain.
• Rimegepant 75mg Orally Disintegrating Tablets (ODT) · Pfizer · Neuroscience
  Rimegepant is a calcitonin gene-related peptide receptor antagonist.
• Zavzpret · Pfizer · Neuroscience
  Zavzpret blocks the action of calcitonin gene-related peptide, a molecule involved in pain transmission.
• Zavegepant 100mg immediate release tablet · Pfizer Inc.
• Rimegepant for acute migraine treatment · Pfizer · Neuroscience
  Rimegepant targets the calcitonin gene-related peptide receptor to treat acute migraine.
• Rimegepant 75mg daily dosing · Pfizer · Neuroscience
  Rimegepant is a calcitonin gene-related peptide receptor antagonist that inhibits the release of pro-inflammatory peptides.
• Miacalcin · Sanofi · Hematology
  Calcitonin salmon acts as a calcitonin receptor agonist, primarily affecting bone, with additional effects on the kidneys and gastrointestinal tract.
• VYEPTI · Lundbeck Seattle BioPharmaceuticals, Inc. · Neuroscience
• Nurtec Odt · Pfizer · Neuroscience
  Rimegepant blocks the calcitonin gene-related peptide receptor.
• Rimegepant 25 MG · Pfizer · Neuroscience
• Osteobios · Sanofi Aventis Us · Metabolic
  Calcitonin salmon acts as a calcitonin receptor agonist, primarily affecting bone, with additional effects on the kidneys and gastrointestinal tract.
• Cibacalcin · Novartis · Hematology
• Intranasal calcitonin · Université de Montréal · Endocrinology / Bone metabolism
  Intranasal calcitonin is a peptide hormone that binds to calcitonin receptors on osteoclasts to inhibit bone resorption and increase bone mineral density.
• Salmon Calcitonin · Eli Lilly and Company · Endocrinology / Bone metabolism
  Salmon calcitonin is a peptide hormone that binds to calcitonin receptors on osteoclasts to inhibit bone resorption and lower serum calcium levels.
• Miacalcin Calcitonin Salmon Nasal Spray · University of Missouri-Columbia · Endocrinology / Bone Metabolism
  Calcitonin salmon is a peptide hormone that binds to calcitonin receptors on osteoclasts to inhibit bone resorption and increase urinary calcium excretion.

Phase 3 pipeline (3)

• Oral Calcitonin Tablets · Tarsa Therapeutics, Inc. · Bone metabolism / Osteoporosis
  Oral calcitonin activates calcitonin receptors on osteoclasts to inhibit bone resorption and reduce bone loss.
• SMC021 Oral Calcitonin · Nordic Bioscience A/S · Endocrinology
  SMC021 Oral Calcitonin works by mimicking the action of the naturally occurring hormone calcitonin to lower blood calcium levels.
• Placebo-matching Ubrogepant · Allergan · Neurology
  Ubrogepant is a calcitonin gene-related peptide receptor antagonist.

Phase 2 pipeline (1)

• BHV-8000 · Biohaven Therapeutics Ltd. · Neurology
  BHV-8000 is a calcitonin gene-related peptide receptor antagonist.

Patent intelligence

• calcitonin patent landscape — aggregated cliff calendar, attackable patents, originator estates